-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOGEN: Q3 2026 IN-PROCESS R&D CHARGE OF ABOUT $284 MLN EXPECTED TO REDUCE GAAP DILUTED EPS BY $1.65, ADJ EPS BY $1.70

Reuters·10/15/2026 21:34:19

Please log in to view news